Encoded to drive first gene therapy into clinic with GV-led $135M series D
With plans to begin human testing of its Dravet syndrome therapy in early 2021, Encoded has raised $135 million in an untranched series D round led by GV that will also fund a natural history study to inform trial endpoints.
Dravet syndrome is primarily considered a pediatric epilepsy disorder and the three approved treatments -- Epidiolex cannabidiol from GW Pharmaceuticals plc (NASDAQ:GWPH); Diacomit stiripentol from Laboratoires Biocodex; and Fintepla fenfluramine from Zogenix Inc. (NASDAQ:ZGNX) -- are indicated for disease-associated seizures...
BCIQ Company Profiles
BCIQ Target Profiles
Sodium voltage-gated channel alpha subunit 1 (Nav1.1) (SCN1A)